A Novel Approach to Treating Nasolabial Fold Wrinkles (smile lines).

Introducing LAVIV™ (azficel-T), the first and only FDA-approved autologous cellular therapy to improve the appearance of moderate to severe nasolabial fold wrinkles in adults1,2

Learn more

News & Upcoming Events

May 3-8, 2012
ASAPS 2012
Vancouver, BC
LAVIV™ education and certification session
Sunday, May 6, 2012

6:30-8:30 PM
Register Online
June 6-10, 2012
Multi Speciality Convention
Las Vegas, NV
LAVIV™ education and certification session
Wednesday, June 6, 2012

2:00-3:00 PM
Register Online
July 19-22, 2012
Cosmetic Boot Camp
Colorado Springs, CO
LAVIV™ education and certification session
Friday, July 20, 2012

3:45-5:00 PM
Register Online

INDICATION

LAVIV™ (azficel-T) is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

The safety and efficacy of LAVIV™ for areas other than the nasolabial folds have not been established.

The efficacy of LAVIV™ beyond six months has not been established.

Please see the Prescribing Information.

IMPORTANT SAFETY INFORMATION

LAVIV™ is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV™ vial is correct.

The most common side effects of LAVIV™ are at the injection site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV™, most injection-site adverse reactions resolved within one week and most required no treatment.

Your health care provider will help you to decide whether you are a candidate for LAVIV™ and may help you avoid some of the adverse reactions from LAVIV™. Before getting LAVIV™, tell your health care provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV™ includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV™ treatment in clinical trials. Talk to your health care provider about these warnings.

Please tell your health care provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV™ if you have a skin infection on your face because LAVIV™ treatment can make the infection worse.

For more information about LAVIV™ please see the Full Prescribing Information.

REFERENCES
  1. LAVIV™ Prescribing Information. Fibrocell Science, Inc. June 2011.
  2. Data on file. Fibrocell Science, Inc. June 2011.